

# PHYSICIANS' DESK REFERENCE®

---

**Medical Consultant**

**Ronald Arky, MD**, Charles S. Davidson Professor of Medicine and Master, Francis Weld Peabody Society, Harvard Medical School

---

**President and Chief Operating Officer, Drug Information Services Group:** Thomas F. Rice

---

**Director of Product Management:** Stephen B. Greenberg

**Associate Product Managers:** Cy S. Cairne, Howard N. Kanter

**National Sales Manager:** James R. Pantaleo

**Senior Account Manager:** Michael S. Sarajian

**Account Managers**

Dikran N. Barsamian

Donald V. Bruccoleri

Lawrence C. Keary

Jeffrey M. Keller

P. Anthony Pinsonault

Anthony Sorce

**Trade Sales Manager:** Robin B. Bartlett

**Trade Sales Account Executive:** Bill Gaffney

**Direct Marketing Manager:** Robert W. Chapman

**Marketing Communications Manager:** Maryann Malorgio

**Director, Professional Support Services:** Mukesh Mehta, RPh

**Drug Information Specialists:** Thomas Fleming, RPh, Marion Gray, RPh

**Editor, Special Projects:** David W. Sifton

**Vice President of Production:** Steven R. Andrezza

**Manager, Database Administration:** Lynne Handler

**Contracts and Support Services Director:** Marjorie A. Duffy

**Director of Production:** Carrie Williams

**Production Managers:** Kimberly Hiller-Vivas, Tara L. Walsh

**Production Coordinators:** Amy B. Douma, Dawn B. McCall

**Format Editors:** Gregory J. Westley, Edna V. Berger

**Index Editor:** Jeffrey Schaefer

**Art Associate:** Joan K. Akerlind

**Director of Corporate Communications:** Gregory J. Thomas

**Electronic Publishing Coordinator:** Joanne M. Pearson

**Electronic Publishing Designer:** Kevin J. Leckner

**Art Director:** Richard A. Weinstock

**Digital Photography:** Shawn W. Cahill, Frank J. McElroy, III

**Director, Circulation & Fulfillment:** Marianne Clarke

**Product Fulfillment Manager:** Stephen Schweikhart



Copyright © 1996 and published by Medical Economics Company at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, PDR For Nonprescription Drugs®, PDR For Ophthalmology®, Pocket PDR®, and The PDR® Family Guide to Prescription Drugs® are registered trademarks used herein under license. PDR® Generics™, PDR Guide to Drug Interactions•Side Effects•Indications™, The PDR® Family Guide to Women's Health and Prescription Drugs™, The PDR® Family Guide to Nutrition and Health™, PDR® Electronic Library™, PDR® Drug Interactions, Side Effects, Indications Diskettes™, and PDR® Drug REAX™ are trademarks used herein under license.

**Officers of Medical Economics:** President and Chief Executive Officer: Norman R. Snesil; President and Chief Operating Officer: Curtis B. Allen; Executive Vice President and Chief Financial Officer: J. Crispin Ashworth; Senior Vice President—Corporate Operations: John R. Ware; Senior Vice President—Corporate Business Development: Raymond M. Zoeller; Vice President, Information Services and Chief Information Officer: Edward J. Zecchini

ISBNs: 1-56363-152-0 and 1-56363-156-3

**SUPER SALMON OIL 1000** OTC  
(1000 mg. Fresh Salmon Oil)

**HOW SUPPLIED**

Super Salmon Oil 1000      **SIZE**      **NDC#**  
100's      10888-4001-5

**ULTRAGUARD** OTC  
(High Potency Antioxidant)

**HOW SUPPLIED**

UltraGuard      **SIZE**      **NDC#**  
60's      10888-0720-3

**ULTRAVIM®** OTC  
(Antioxidant Multivitamin)

**HOW SUPPLIED**

UltraVim®      **SIZE**      **NDC#**  
60's      10888-5313-3

**XL-1** OTC  
(Multivitamin Liquid with Minerals)

**HOW SUPPLIED**

XL-1      **SIZE**      **NDC#**  
8 oz.      10888-8710-1

**Akorn, Inc.**  
100 AKORN DRIVE  
ABITA SPRINGS, LA 70420

Direct Inquiries to:  
Customer Service  
(800) 535-7155  
(504) 893-9300

**OPHTHALMIC PRODUCTS**

For information on Akorn ophthalmic pharmaceutical products, consult the PDR For Ophthalmology. For literature, sample material or service items, please contact Akorn, Inc. directly. (800) 535-7155

**Alcon Laboratories, Inc.**  
and its affiliates  
**CORPORATE HEADQUARTERS**  
PO BOX 6600  
6201 SOUTH FREEWAY  
FORT WORTH, TX 76134

Direct Inquiries to:  
Sales Services  
(817) 293-0450

For Medical Information Contact:  
Medical Department  
P.O. Box 6380  
Fort Worth, TX 76115  
(817) 293-0450

**OPHTHALMIC PRODUCTS**


For information on Alcon ophthalmic products, consult the PDR For Ophthalmology. See a complete listing of products in the Manufacturers' Index section of this book. For information, literature, samples or service items contact Alcon Sales Services.

**ALOMIDE® 0.1%** B  
(Lodoxamide Tromethamine Ophthalmic Solution)

**DESCRIPTION**

white, crystalline, water-soluble powder with a molecular weight of 553.91. The chemical structure is presented below:

**Structural Formula:**



**Chemical Name:**

N,N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid tromethamine salt

Empirical Formula: C<sub>19</sub>H<sub>28</sub>O<sub>12</sub>N<sub>5</sub>Cl

Each mL of **ALOMIDE® Ophthalmic Solution** contains: Active: 1.78 mg lodoxamide tromethamine equivalent to 1 mg lodoxamide. Preservative: benzalkonium chloride 0.007%. Inactive: mannitol, hydroxypropyl methylcellulose 2910, sodium citrate, citric acid, edetate disodium, tyloxapol, hydrochloric acid and/or sodium hydroxide (adjust pH), and purified water.

**CLINICAL PHARMACOLOGY**

Lodoxamide tromethamine is a mast cell stabilizer that inhibits the *in vivo* Type 1 immediate hypersensitivity reaction. Lodoxamide therapy inhibits the increases in cutaneous vascular permeability that are associated with reagin or IgE and antigen-mediated reactions.

*In vitro* studies have demonstrated the ability of lodoxamide to stabilize rodent mast cells and prevent antigen-stimulated release of histamine. In addition, lodoxamide prevents the release of other mast cell inflammatory mediators (i.e., SRS-A, slow-reacting substances of anaphylaxis, also known as the peptidoleukotrienes) and inhibits eosinophil chemotaxis. Although lodoxamide's precise mechanism of action is unknown, the drug has been reported to prevent calcium influx into mast cells upon antigen stimulation.

Lodoxamide has no intrinsic vasoconstrictor, antihistaminic, cyclooxygenase inhibition, or other anti-inflammatory activity.

The disposition of <sup>14</sup>C-lodoxamide was studied in six healthy adult volunteers receiving a 3 mg (50 µCi) oral dose of lodoxamide. Urinary excretion was the major route of elimination. The elimination half-life of <sup>14</sup>C-lodoxamide was 8.5 hours in urine. In a study conducted in twelve healthy adult volunteers, topical administration of **ALOMIDE® 0.1%** (Lodoxamide Tromethamine Ophthalmic Solution), one drop in each eye four times per day for ten days, did not result in any measurable lodoxamide plasma levels at a detection limit of 2.5 ng/mL.

**INDICATIONS AND USAGE**

**ALOMIDE® Ophthalmic Solution 0.1%** is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

**CONTRAINDICATIONS**

Hypersensitivity to any component of this product.

**WARNINGS**

Not for injection. As with all ophthalmic preparations containing benzalkonium chloride, patients should be instructed not to wear soft contact lenses during treatment with **ALOMIDE® Ophthalmic Solution**.

**PRECAUTIONS**

**General:** Patients may experience a transient burning or stinging upon instillation of **ALOMIDE® Ophthalmic Solution**. Should these symptoms persist, the patient should be advised to contact the prescribing physician.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:**

A long-term study with lodoxamide tromethamine in rats (two-year oral administration) showed no neoplastic or tumorigenic effects at doses 100 mg/kg/day (more than 5000 times the proposed human clinical dose). No evidence of mutagenicity or genetic damage was seen in the Ames *Salmonella* Assay, Chromosomal Aberration in CHO Cells Assay, or Mouse Forward Lymphoma Assay. In the BALB/c-3T3 Cells Transformation Assay, some increase in the number of transformed foci was seen at high concentrations (greater than 4000 µg/mL). No evidence of impairment of reproductive function was shown in laboratory animal studies.

**Pregnancy: Pregnancy Category B.** Reproduction studies with lodoxamide tromethamine administered orally to rats and rabbits in doses of 100 mg/kg/day (more than 5000 times the proposed human clinical dose) produced no evidence of developmental toxicity. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, **ALOMIDE® 0.1%** (Lodoxamide Tromethamine Ophthalmic Solution) should be used during preg-

drugs are excreted in human milk, caution should be exercised when **ALOMIDE® Ophthalmic Solution 0.1%** is administered to nursing women.

**Pediatric Use:** Safety and effectiveness in pediatric patients below the age of 2 have not been established.

**ADVERSE REACTIONS**

During clinical studies of **ALOMIDE® Ophthalmic Solution 0.1%**, the most frequently reported ocular adverse experiences were transient burning, stinging, or discomfort upon instillation, which occurred in approximately 15% of the subjects. Other ocular events occurring in 1 to 5% of the subjects included ocular itching/pruritus, blurred vision, dry eye, tearing/discharge, hyperemia, crystalline deposits, and foreign body sensation. Events that occurred in less than 1% of the subjects included corneal erosion/ulcer, scales on lid/lash, eye pain, ocular edema/swelling, ocular warming sensation, ocular fatigue, chemosis, corneal abrasion, anterior chamber cells, keratopathy/keratitis, blepharitis, allergy, sticky sensation, and epitheliopathy.

Nonocular events reported were headache (1.5%) and (at less than 1%) heat sensation, dizziness, somnolence, nausea, stomach discomfort, sneezing, dry nose, and rash.

**OVERDOSAGE**

There have been no reports of **ALOMIDE® 0.1%** (Lodoxamide Tromethamine Ophthalmic Solution) overdose following topical ocular application. Accidental overdose of an oral preparation of 120 to 180 mg of lodoxamide resulted in a temporary sensation of warmth, profuse sweating, diarrhea, light-headedness, and a feeling of stomach distension; no permanent adverse effects were observed. Side effects reported following systemic oral administration of 0.1 mg to 10.0 mg of lodoxamide include a feeling of warmth or flushing, headache, dizziness, fatigue, sweating, nausea, loose stools, and urinary frequency/urgency. The physician may consider emesis in the event of accidental ingestion.

**DOSAGE AND ADMINISTRATION**

The dose for adults and children greater than two years of age is one to two drops in each affected eye four times daily for up to 3 months.

**HOW SUPPLIED**

**ALOMIDE® Ophthalmic Solution 0.1%** is supplied as follows: 10 mL in plastic ophthalmic DROP-TAINER® dispenser.

10 mL: NDC 0065-0345-10

**STORAGE**

Store at 15°C-27°C (59°F-80°F).

**CAUTION**


Federal (USA) law prohibits dispensing without prescription.

**BETOPTIC®**

(betaxolol hydrochloride)  
0.5% as base  
Sterile Ophthalmic Solution

**DESCRIPTION**

**BETOPTIC® Sterile Ophthalmic Solution** contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molecular weight of 343.89. The chemical structure is presented below:



**Empirical Formula:**

C<sub>18</sub>H<sub>29</sub>NO<sub>3</sub> · HCl

**Chemical Name:**

(±)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride.

Each mL of **BETOPTIC® Ophthalmic Solution (0.5%)** contains: Active: 5.6 mg betaxolol hydrochloride equivalent to betaxolol base 5 mg. Preservative: Benzalkonium Chloride 0.01%. Inactives: Edetate Disodium, Sodium Chloride, Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH), and Purified Water.

**CLINICAL PHARMACOLOGY**

Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor blocking agent, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic blocking agents reduce cardiac output in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect